2014年BestofASCO大会详细日程.doc.docVIP

2014年临床肿瘤学新进展学术研讨会―― Best of ASCO? Event in China 2014 会议日程Program 会议第一天 2014年7月11日 (Day 1, July 11, 2014) 8:00–8:15 开幕式 (Opening Ceremony) CSCO代表：吴一龙教授 致辞 (Opening speech by Prof. Yi-Long Wu on behalf of CSCO) ASCO代表：Peter Yu教授 致辞 (Opening speech by Prof. Peter Yu on behalf of ASCO) 血液肿瘤专场 (Hematologic Malignancy) 主席(Chair)：马 军(Jun Ma)、王健民(Jian-Min Wang) 时间(Time) 题目(Topic) 讲者(Speaker) 8:15–8:40 Abstract 7005^ Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). BiTE antibody blinatumomab在复发/难治性急性前体B淋巴细胞白血病患者（r/ r ALL）的验证性多中心、开放标签的单臂2期研究。 糜坚青(Jian-Qing Mi) Abstract 7008 Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. ibrutinib与ofatumumab在复发或难治性（R/R）慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机比较：来自RESONATE Ⅲ期试验的结果。 Abstract 7026 Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial. Ruxolitinib（RUX）在羟基脲耐药或不能耐受的真性红细胞增多症（PV）患者的前瞻性、随机、开放标签的Ⅲ期研究结果：RESPONSE试验。 8:40–8:50 专家评述 Discussion Topic: A comprehensive overview on molecular targeted therapy for leukemia 讨论主题：白血病分子靶向治疗综述 李建勇(Jian-Yong Li) 8:50–8:55 讨论(Q A) 马 军(Jun Ma) 王健民(Jian-Min Wang) 李建勇(Jian-Yong Li) 泌尿系统肿瘤专场1 (Genitourinary Cancer Session 1) 主席(Chair)：叶定伟(Ding-Wei Ye)、马建辉(Jian-Hui Ma) 时间(Time) 题目(Topic) 讲者(Speaker) 8:55–9:20 Abstract LBA2 Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. 一项ECOG领导的 III期随机临床试验：激素敏感的新发转移性前列腺癌患者（mPrCa）接受化疗联合内分泌治疗对比单用内分泌治疗对于总生存期(OS)的影响。 戴 波(Bo Dai) Abstract 5003 Immediate versus deferred initiation of androgen deprivation therapy in prostate c